Skip to main content
editorial
. 2012 Jul 7;18(25):3183–3195. doi: 10.3748/wjg.v18.i25.3183

Table 2.

Ghrelin antagonists under development for the treatment of obesity and type 2 diabetes

Ghrelin antagonists
Drug Company Target Status
TZP-301 Tranzyme Pharma Obesity, metabolic syndrome Lead optimization
Two families of ghrelin antagonists Helsinn Pharmaceuticals Obesity, metabolic syndrome Lead optimization
AEZS-123 Aeterna Zenartis Obesity, alcohol abuse Preclinical
Ghrelin antagonist Novartis (Elixir) Type 2 diabetes, obesity Preclinical